News Headlines Article

Why is CMS examining Medicare coverage for depression treatments?
Modern Healthcare

The Medicare Evidence Development and Coverage Advisory Committee on Wednesday will discuss and vote on the definition of treatment-resistant depression and advise the CMS on coverage.But mental health trade groups and Medicare beneficiary advocates don’t know why the CMS felt the need to convene MEDCAC to discuss the issue. None could point to any major-related concerns. A CMS spokesman did not immediately respond to a request for comment. What is clear is that antidepressants accounted for some of the most costly drugs covered by Medicare Part D. Spending on two of the most common drugs totaled $4 billion last year.